טוען...
The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses
AIM: To evaluate the potential effects of therapeutic and supratherapeutic doses of linagliptin (BI 1356) on the QT/QT(c) interval in healthy subjects. METHODS: The study was a randomized, double-blind, placebo-controlled, four-period crossover study using single oral doses of linagliptin (5 mg and...
שמור ב:
| Main Authors: | , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Blackwell Science Inc
2011
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3141185/ https://ncbi.nlm.nih.gov/pubmed/21306414 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2011.03931.x |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|